Selank
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Selank is listed as nootropic / anxiolytic.
- •Anxiety
- •Cognitive enhancement
- •Immunomodulation
Regulatory status: Approved in Russia; not FDA-approved.
Structure & Properties
Compound: Selank; also known as TP-7.
Pharmacologic class: Nootropic / Anxiolytic.
Known delivery routes: Intranasal, Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Synthetic tuftsin analog — modulates GABA-A activity; increases BDNF expression; reduces enkephalin degradation; anti-inflammatory via IL-6.
- •Anxiolytic without sedation
- •Improved focus and mood
- •No dependence reported in Russian data
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Russian Phase II/III; limited Western RCTs
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Intranasal, 2–3× daily. Take during periods of stress or before cognitively demanding work. No food interaction.
Potential interactions and combinations to avoid
- •Concurrent benzodiazepines without oversight — additive anxiolysis
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Mild sedation
- •Headache
- •Limited Western safety review
Contraindications
- •Pregnancy
- •Hypersensitivity
- •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- •Bipolar disorder, psychosis, or active mania
- •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- •Recent intracranial haemorrhage or unstable neurologic injury
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 250–500 mcg/day
Frequency: Once or twice daily
Cycling: 2–4 week courses, then 2-week break.
Intranasal
Standard route — 0.15% solution.
Nasal spray or dropper. 1–3 drops per nostril, 2–3× daily. Do not sniff hard.
Subcutaneous
Alternative if nasal irritation.
Insulin syringe. SubQ abdomen, once daily.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Semax (alternating days or different times of day)
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Morning or early afternoon — intranasal; calming but non-sedating.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Intranasal — Alternate nostrils, spray on inhalation, do not sniff hard.
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
2–4 week courses, then 2-week break.
Timing & Interactions
- ·Concurrent benzodiazepines without oversight — additive anxiolysis
- ·Semax (alternating days or different times of day)
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Selank and sync them to Vial Lab.
Benefits
- ·Anxiolytic without sedation
- ·Improved focus and mood
- ·No dependence reported in Russian data
Risks
- ·Mild sedation
- ·Headache
- ·Limited Western safety review
Contraindications
- ·Pregnancy
- ·Hypersensitivity
- ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- ·Bipolar disorder, psychosis, or active mania
- ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- ·Recent intracranial haemorrhage or unstable neurologic injury
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Approved in Russia; not FDA-approved
Veterinary Use (Pets)
No established veterinary protocol for Selank. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.